9 June 2011
Responding to the Rarer Cancers Foundation ‘Funding cancer drugs’ report released today, Mike Hobday, Head of Policy of Macmillan Cancer Support, said:
'Many cancer patients have received life extending drugs because of the interim Cancer Drugs Fund in England. However, this report from the Rarer Cancers Foundation is further evidence of the significant variation in the way that it has been administered between regions. It is unacceptable that people with rarer cancers are still losing out on getting the cancer drugs they so desperately need.
'Every cancer patient should get the drugs their doctor recommends, regardless of what type of cancer they have, or where they live. It is vital that the Government's excellent initiative in introducing the Cancer Drugs Fund mustn’t be held back by uneven regional implementation.
'To prevent this postcode lottery the Government must develop best practice advice to complement national guidance, and ensure this knowledge is shared between different regions to prevent unnecessary variation. It is crucial that funding decisions are monitored effectively and all funding decisions should meet the 31-day cancer treatment standard.'
For further information, please contact:
Sarah Ross, Senior Media & PR Officer of Macmillan Cancer Support
020 7840 7821 (out of hours 07801 307068)
Notes to Editors:
About Macmillan Cancer Support
Macmillan Cancer Support improves the lives of people affected by cancer, providing practical, medical, emotional and financial support. Working alongside people affected by cancer, Macmillan works to improve cancer care. One in three of us will get cancer. Two million of us are living with it. If you are affected by cancer Macmillan can help.
For more information about Macmillan Cancer Support, visit www.macmillan.org.uk or freephone 0800 500 800 for an information pack.